MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
PLRZ — Polyrizon Ltd. Ordinary Shares
NasdaqPolyrizon Ltd. Ordinary Shares
$9.15
-0.52(-5.37%)
- O
- 9.28
- H
- 9.28
- L
- 9.00
- V
- 5.06K
⏱️ End-of-day dataAs of Oct 7, 2026
PLRZ — Latest News & Headlines
6 StoriesA material that sticks to nasal tissue could deliver medicines. Polyrizon filed a U.S. patent application. - Stock Titan
A material that sticks to nasal tissue could deliver medicines. Polyrizon filed a U.S. patent application. Stock Titan
Polyrizon Files New U.S. Patent Application for Mucoadhesive Nasal Drug Delivery Platform - Quiver Quantitative
Polyrizon Files New U.S. Patent Application for Mucoadhesive Nasal Drug Delivery Platform Quiver Quantitative
Polyrizon Ltd. SEC Filing (Oct 2, 2026) - Stock Titan
Polyrizon Ltd. SEC Filing (Oct 2, 2026) Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. Stock Titan
Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss - TipRanks
Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss TipRanks
Polyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery Platform - TipRanks
Polyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery Platform TipRanks